Related Experiment Video
Updated: Aug 10, 2026

Conducting Maximal and Submaximal Endurance Exercise Testing to Measure Physiological and Biological Responses to Acute Exercise in Humans
Published on: October 17, 2018
Exercise capacity and quality of life in the treatment of heart failure
R Blackwood1, R A Mayou, J C Garnham
1Cardiac Research Unit, Wexham Park Hospital, Slough.
Insights
Heart failure patients showed similar improvements in exercise and quality of life across active treatments and placebo. Special heart failure clinics may offer therapeutic benefits beyond medication.
Area of Science:
- Cardiology
- Clinical Trials
- Quality of Life Research
Background:
- The relationship between exercise capacity and symptomatic/functional status in heart failure patients remains unclear.
- Evaluating treatment efficacy requires robust measures of both exercise capacity and quality of life.
Purpose of the Study:
- To compare the effects of digoxin, xamoterol, and placebo on exercise capacity and quality of life in heart failure patients.
- To establish quantitative measures for quality-of-life variables and assess their correlation with exercise capacity.
- To validate the use of exercise capacity and quality-of-life measurements in heart failure treatment evaluation.
Main Methods:
- A double-blind, placebo-controlled study involving patients with heart failure.
- Comparison of two active treatments (digoxin and xamoterol) against a placebo.
- Development and application of quantitative measures for quality-of-life variables.
Main Results:
- All groups, including placebo, demonstrated improvements in exercise capacity and quality of life without significant differences between treatments.
- The placebo effect was substantial, likely due to increased medical and research staff attention, highlighting the value of specialized heart failure clinics.
- Significant correlations were found between changes in exercise duration and various quality-of-life indicators (e.g., breathlessness, mood, daily task difficulty).
Conclusions:
- Measuring changes in exercise capacity is a valid approach for evaluating heart failure treatment.
- Quantitative quality-of-life measurements significantly contribute to the comprehensive assessment of heart failure therapies.
- The attention provided in specialized heart failure clinics may have a considerable therapeutic impact on patients.
Abstract:
In a double-blind study comparing two active treatments (digoxin and xamoterol) and placebo in patients with heart failure, improvements in exercise capacity and quality of life were observed in all three groups, with no significant differences. The substantial benefits seen in the placebo group were probably the result of increased attention from the medical and research staff and suggest the therapeutic value of special heart failure clinics. The relationship between exercise and symptomatic/functional status has been unclear. We developed quantitative measures of quality-of-life variables and examined their relationship with exercise capacity. There were significant relationships between change in exercise duration and changes in breathlessness, tiredness, chest pain, walking difficulty, rate of walking, difficulty with daily tasks, speed of daily tasks, mood, and sleeping. This study confirms the validity of measuring change in exercise capacity and demonstrates that specific measurements of quality of life make an important contribution to the evaluation of the treatment of heart failure.
Related Concept Videos
Pathophysiology of Heart Failure
Exercise and Cardiac Output
Sustained exercise increases the muscles' oxygen demand, which can be met...
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions

